Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab Deruxtecan
← catalyst calendarSponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
228actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-20 | actual | When the study began enrolling |
| Primary completion | 2025-06-16 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-16 | actual | The whole study's end, after follow-up |
| First posted | 2025-02-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- HER2-positive Breast Cancer
Intervention
- Other: No drug
Primary outcome
what the primary-completion date above is the date OFReal-world Progression-free Survival (rwPFS)
measured Index date (index LOT start date) to date of earliest disease progression >14 days after the index date or date of death, whichever occurs first, up to approximately 13 years 3 months
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed